Fusion Gene Studies
in Kim Lab

FusionBase FusionGDB FusionGDB2 FusionPDB FusionNeoAntigen FusionAI FusionNW FGviewer Publication Contact
FusionGDB Logo

Home

Download

Statistics

Examples

Help

Contact

Center for Computational Systems Medicine
leaf

Fusion Gene Summary

leaf

Fusion Gene ORF analysis

leaf

Fusion Genomic Features

leaf

Fusion Protein Features

leaf

Fusion Gene Sequence

leaf

Fusion Gene PPI analysis

leaf

Related Drugs

leaf

Related Diseases

Fusion gene:ASXL2-IDH1 (FusionGDB2 ID:HG55252TG3417)

Fusion Gene Summary for ASXL2-IDH1

check button Fusion gene summary
Fusion gene informationFusion gene name: ASXL2-IDH1
Fusion gene ID: hg55252tg3417
HgeneTgene
Gene symbol

ASXL2

IDH1

Gene ID

55252

3417

Gene nameASXL transcriptional regulator 2isocitrate dehydrogenase (NADP(+)) 1
SynonymsASXH2|SHAPNSHEL-216|HEL-S-26|IDCD|IDH|IDP|IDPC|PICD
Cytomap('ASXL2')('IDH1')

2p23.3

2q34

Type of geneprotein-codingprotein-coding
Descriptionputative Polycomb group protein ASXL2additional sex combs like 2, transcriptional regulatoradditional sex combs-like protein 2polycomb group protein ASXH2isocitrate dehydrogenase [NADP] cytoplasmicNADP(+)-specific ICDHNADP-dependent isocitrate dehydrogenase, cytosolicNADP-dependent isocitrate dehydrogenase, peroxisomalepididymis luminal protein 216epididymis secretory protein Li 26epididymis secretor
Modification date2020031320200313
UniProtAcc

Q76L83

.
Ensembl transtripts involved in fusion geneENST00000435504, ENST00000272341, 
ENST00000336112, ENST00000404843, 
ENST00000497092, 
Fusion gene scores* DoF score18 X 11 X 10=19806 X 5 X 3=90
# samples 246
** MAII scorelog2(24/1980*10)=-3.04439411935845
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(6/90*10)=-0.584962500721156
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Context

PubMed: ASXL2 [Title/Abstract] AND IDH1 [Title/Abstract] AND fusion [Title/Abstract]

Most frequent breakpointASXL2(26101035)-IDH1(209116291), # samples:1
Anticipated loss of major functional domain due to fusion event.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneASXL2

GO:0035360

positive regulation of peroxisome proliferator activated receptor signaling pathway

21047783

HgeneASXL2

GO:0045600

positive regulation of fat cell differentiation

21047783

HgeneASXL2

GO:0045944

positive regulation of transcription by RNA polymerase II

21047783

TgeneIDH1

GO:0006102

isocitrate metabolic process

10521434|19935646|20171178

TgeneIDH1

GO:0006103

2-oxoglutarate metabolic process

19935646



check button Fusion gene information
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
SourceDiseaseSampleHgeneHchrHbpHstrandTgeneTchrTbpTstrand
ChimerDB4PRADTCGA-XJ-A9DK-01AASXL2chr2

26101035

-IDH1chr2

209116291

-


Top

Fusion Gene ORF analysis for ASXL2-IDH1

check button Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
ORFHenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrand
5CDS-5UTRENST00000435504ENST00000345146ASXL2chr2

26101035

-IDH1chr2

209116291

-
5CDS-5UTRENST00000435504ENST00000415913ASXL2chr2

26101035

-IDH1chr2

209116291

-
5CDS-5UTRENST00000435504ENST00000446179ASXL2chr2

26101035

-IDH1chr2

209116291

-
5UTR-5UTRENST00000272341ENST00000345146ASXL2chr2

26101035

-IDH1chr2

209116291

-
5UTR-5UTRENST00000272341ENST00000415913ASXL2chr2

26101035

-IDH1chr2

209116291

-
5UTR-5UTRENST00000272341ENST00000446179ASXL2chr2

26101035

-IDH1chr2

209116291

-
5UTR-5UTRENST00000336112ENST00000345146ASXL2chr2

26101035

-IDH1chr2

209116291

-
5UTR-5UTRENST00000336112ENST00000415913ASXL2chr2

26101035

-IDH1chr2

209116291

-
5UTR-5UTRENST00000336112ENST00000446179ASXL2chr2

26101035

-IDH1chr2

209116291

-
intron-5UTRENST00000404843ENST00000345146ASXL2chr2

26101035

-IDH1chr2

209116291

-
intron-5UTRENST00000404843ENST00000415913ASXL2chr2

26101035

-IDH1chr2

209116291

-
intron-5UTRENST00000404843ENST00000446179ASXL2chr2

26101035

-IDH1chr2

209116291

-
intron-5UTRENST00000497092ENST00000345146ASXL2chr2

26101035

-IDH1chr2

209116291

-
intron-5UTRENST00000497092ENST00000415913ASXL2chr2

26101035

-IDH1chr2

209116291

-
intron-5UTRENST00000497092ENST00000446179ASXL2chr2

26101035

-IDH1chr2

209116291

-

check buttonORFfinder result based on the fusion transcript sequence of in-frame fusion genes.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score

Top

Fusion Genomic Features for ASXL2-IDH1


check buttonFusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints.
HgeneHchrHbpHstrandTgeneTchrTbpTstrand1-pp (fusion gene breakpoint)


Top

Fusion Protein Features for ASXL2-IDH1


check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:26101035/:209116291)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonMain function of each fusion partner protein. (from UniProt)
HgeneTgene
ASXL2

Q76L83

.
FUNCTION: Putative Polycomb group (PcG) protein. PcG proteins act by forming multiprotein complexes, which are required to maintain the transcriptionally repressive state of homeotic genes throughout development. PcG proteins are not required to initiate repression, but to maintain it during later stages of development. They probably act via methylation of histones, rendering chromatin heritably changed in its expressibility (By similarity). Involved in transcriptional regulation mediated by ligand-bound nuclear hormone receptors, such as peroxisome proliferator-activated receptor gamma (PPARG). Acts as coactivator for PPARG and enhances its adipocyte differentiation-inducing activity; the function seems to involve differential recruitment of acetylated and methylated histone H3. {ECO:0000250, ECO:0000269|PubMed:21047783}.FUNCTION: Transcriptional activator which is required for calcium-dependent dendritic growth and branching in cortical neurons. Recruits CREB-binding protein (CREBBP) to nuclear bodies. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP (By similarity). {ECO:0000250}.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at

download page


* Minus value of BPloci means that the break pointn is located before the CDS.
- In-frame and retained protein feature among the 13 regional features.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

- In-frame and not-retained protein feature among the 13 regional features.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note


Top

Fusion Gene Sequence for ASXL2-IDH1


check button For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones.

Top

Fusion Gene PPI Analysis for ASXL2-IDH1


check button Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in

ChiPPI page.


check button Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160)
HgeneHgene's interactorsTgeneTgene's interactors


check button - Retained PPIs in in-frame fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenStill interaction with


check button - Lost PPIs in in-frame fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenInteraction lost with


check button - Retained PPIs, but lost function due to frame-shift fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenInteraction lost with


Top

Related Drugs for ASXL2-IDH1


check button Drugs targeting genes involved in this fusion gene.
(DrugBank Version 5.1.8 2021-05-08)
PartnerGeneUniProtAccDrugBank IDDrug nameDrug activityDrug typeDrug status

Top

Related Diseases for ASXL2-IDH1


check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
HgeneASXL2C0005684Malignant neoplasm of urinary bladder1CTD_human
HgeneASXL2C0005695Bladder Neoplasm1CTD_human
HgeneASXL2C0023467Leukemia, Myelocytic, Acute1CTD_human
HgeneASXL2C0026998Acute Myeloid Leukemia, M11CTD_human
HgeneASXL2C1879321Acute Myeloid Leukemia (AML-M2)1CTD_human
HgeneASXL2C4310672SHASHI-PENA SYNDROME1GENOMICS_ENGLAND
TgeneC0017638Glioma5CGI;CTD_human;UNIPROT
TgeneC0259783mixed gliomas5CTD_human
TgeneC0555198Malignant Glioma5CTD_human
TgeneC0013366Dyschondroplasias2ORPHANET
TgeneC0014084Enchondromatosis2CTD_human;GENOMICS_ENGLAND;ORPHANET
TgeneC0023467Leukemia, Myelocytic, Acute2CGI;CTD_human
TgeneC0024454Maffucci Syndrome2CTD_human;GENOMICS_ENGLAND;ORPHANET
TgeneC0026998Acute Myeloid Leukemia, M12CTD_human
TgeneC0936248Chondroma2CTD_human
TgeneC1704356Enchondroma2CTD_human
TgeneC1879321Acute Myeloid Leukemia (AML-M2)2CTD_human
TgeneC3553958METAPHYSEAL ENCHONDROMATOSIS WITH D-2-HYDROXYGLUTARIC ACIDURIA2GENOMICS_ENGLAND;ORPHANET
TgeneC0018916Hemangioma1CTD_human
TgeneC0023452Childhood Acute Lymphoblastic Leukemia1CTD_human
TgeneC0023453L2 Acute Lymphoblastic Leukemia1CTD_human
TgeneC0023487Acute Promyelocytic Leukemia1CTD_human
TgeneC0027643Neoplasm Recurrence, Local1CTD_human
TgeneC0028945oligodendroglioma1CTD_human
TgeneC0033578Prostatic Neoplasms1CTD_human
TgeneC0205788Histiocytoid hemangioma1CTD_human
TgeneC0205789Hemangioma, Intramuscular1CTD_human
TgeneC0206698Cholangiocarcinoma1CGI;CTD_human
TgeneC0206726gliosarcoma1ORPHANET
TgeneC0279070Adult Oligodendroglioma1CTD_human
TgeneC0280475Childhood Oligodendroglioma1CTD_human
TgeneC0280793Mixed Oligodendroglioma-Astrocytoma1CTD_human
TgeneC0334588Giant Cell Glioblastoma1ORPHANET
TgeneC0334590Anaplastic Oligodendroglioma1CTD_human
TgeneC0344461Oligodendroblastoma1CTD_human
TgeneC0345905Intrahepatic Cholangiocarcinoma1CTD_human
TgeneC0376358Malignant neoplasm of prostate1CTD_human
TgeneC0677608Chorioangioma1CTD_human
TgeneC0751395Mixed Oligodendroglioma-Ependymoma1CTD_human
TgeneC0751396Well Differentiated Oligodendroglioma1CTD_human
TgeneC1959588Angioma1CTD_human
TgeneC1961102Precursor Cell Lymphoblastic Leukemia Lymphoma1CTD_human
TgeneC2239176Liver carcinoma1CTD_human
TgeneC3805278Extrahepatic Cholangiocarcinoma1CTD_human